Juncture Wealth Strategies LLC Sells 1,290 Shares of Vericel Co. (NASDAQ:VCEL)

Juncture Wealth Strategies LLC decreased its stake in shares of Vericel Co. (NASDAQ:VCEL) by 11.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 10,353 shares of the biotechnology company’s stock after selling 1,290 shares during the period. Juncture Wealth Strategies LLC’s holdings in Vericel were worth $568,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of VCEL. International Assets Investment Management LLC lifted its holdings in shares of Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares in the last quarter. Farther Finance Advisors LLC grew its position in Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 322 shares during the period. Meeder Asset Management Inc. acquired a new position in Vericel in the 3rd quarter valued at $92,000. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,240 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a research note on Tuesday, November 19th. BTIG Research raised their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stephens reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Wednesday, January 15th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Vericel has an average rating of “Moderate Buy” and a consensus target price of $62.14.

Vericel Trading Up 0.0 %

NASDAQ VCEL opened at $57.43 on Friday. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $61.49. The company has a market cap of $2.83 billion, a P/E ratio of 957.33 and a beta of 1.72. The company has a fifty day simple moving average of $57.40 and a 200 day simple moving average of $50.47.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The business had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Sell-side analysts predict that Vericel Co. will post 0.12 EPS for the current year.

Insider Activity at Vericel

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total value of $150,000.00. Following the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. This represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Paul K. Wotton sold 2,600 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total value of $152,672.00. Following the completion of the sale, the director now directly owns 27,402 shares in the company, valued at approximately $1,609,045.44. The trade was a 8.67 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,100 shares of company stock worth $889,872. Company insiders own 5.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.